PT1318837E - Metodo de tratamenton de carcinoma positivo a receptor de estrogenio - Google Patents
Metodo de tratamenton de carcinoma positivo a receptor de estrogenioInfo
- Publication number
- PT1318837E PT1318837E PT01961914T PT01961914T PT1318837E PT 1318837 E PT1318837 E PT 1318837E PT 01961914 T PT01961914 T PT 01961914T PT 01961914 T PT01961914 T PT 01961914T PT 1318837 E PT1318837 E PT 1318837E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- carcinoma positive
- estrogene
- receptor
- carcinoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22432600P | 2000-08-11 | 2000-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1318837E true PT1318837E (pt) | 2004-12-31 |
Family
ID=22840171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01961914T PT1318837E (pt) | 2000-08-11 | 2001-08-06 | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio |
Country Status (15)
Country | Link |
---|---|
US (1) | US6511986B2 (pt) |
EP (1) | EP1318837B1 (pt) |
JP (1) | JP2004507465A (pt) |
CN (1) | CN100448487C (pt) |
AR (1) | AR033555A1 (pt) |
AT (1) | ATE278421T1 (pt) |
AU (1) | AU2001283139A1 (pt) |
CA (1) | CA2416976C (pt) |
DE (1) | DE60106281T2 (pt) |
DK (1) | DK1318837T3 (pt) |
ES (1) | ES2228932T3 (pt) |
HK (1) | HK1056687A1 (pt) |
MX (1) | MXPA03001245A (pt) |
PT (1) | PT1318837E (pt) |
WO (1) | WO2002013802A2 (pt) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215445A1 (en) * | 1997-05-23 | 2003-11-20 | Ginette Serrero | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
US7091047B2 (en) * | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
US6720159B1 (en) | 1997-12-16 | 2004-04-13 | A&G Pharmaceutical, Inc. | 88KDA tumorigenic growth factor and antagonists |
US6309826B1 (en) | 1997-05-23 | 2001-10-30 | Ginette Serrero | 88kDa tumorigenic growth factor and antagonists |
US8512960B2 (en) * | 1997-05-23 | 2013-08-20 | A&G Pharmaceutical, Inc. | 88kDa tumorigenic growth factor and antagonists |
US6881548B2 (en) * | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
US20100111928A1 (en) * | 1997-05-23 | 2010-05-06 | A & G Pharmaceutical, Inc. | Methods and kits for diagnosis tumorgenicity |
US7617145B1 (en) * | 2000-10-24 | 2009-11-10 | Worldwide Farm Equipment Auctions.Com Ltd. | Adaptive bidding increments in an online auction system |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
AU2016206379B2 (en) * | 2001-02-19 | 2017-09-14 | Novartis Ag | Cancer Treatment |
LT3143995T (lt) * | 2001-02-19 | 2019-01-25 | Novartis Ag | Rapamicino darinys, skirtas plaučių vėžio gydymui |
AU2011226833B9 (en) * | 2001-02-19 | 2014-07-03 | Novartis Ag | Cancer treatment |
ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
AU2002318225B2 (en) * | 2001-07-09 | 2007-12-13 | Repros Therapeutics Inc. | Methods and materials for the treatment of testosterone deficiency in men |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
KR101004224B1 (ko) | 2002-02-01 | 2010-12-27 | 어리어드 파마슈티칼스, 인코포레이티드 | 인 함유 화합물 및 이의 용도 |
AU2003243226A1 (en) * | 2002-05-15 | 2003-12-02 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
US7411045B2 (en) * | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
EP1601687B1 (en) * | 2003-02-26 | 2010-10-06 | A & G Pharmaceuticals, Inc. | Methods for increasing the proliferation of b cells |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
CA2519338A1 (en) * | 2003-04-22 | 2004-11-04 | Wyeth | Antineoplastic combinations |
EP1644038A2 (en) * | 2003-06-23 | 2006-04-12 | A & G Pharmaceuticals, Inc. | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
CN1829514A (zh) * | 2003-07-25 | 2006-09-06 | 惠氏公司 | Cci-779冻干制剂 |
EP1660010B1 (en) * | 2003-08-01 | 2013-07-24 | A & G Pharmaceutical, Inc. | Compositions and methods for restoring sensitivity to treatment with her2 antagonists |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
CN101048152A (zh) * | 2004-10-28 | 2007-10-03 | 惠氏公司 | mTOR抑制剂在治疗子宫平滑肌瘤中的应用 |
PT1848414E (pt) * | 2005-02-03 | 2011-05-25 | Gen Hospital Corp | M?todo para tratamento de cancro resistente a gefitinib |
WO2006096325A1 (en) | 2005-03-07 | 2006-09-14 | Wyeth | Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin |
EP1863816B1 (en) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
NZ560551A (en) * | 2005-03-22 | 2010-02-26 | Repros Therapeutics Inc | Dosing regimes for trans-clomiphene |
CN103893778A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
EP2382995A3 (en) * | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
AR057854A1 (es) | 2005-11-04 | 2007-12-19 | Wyeth Corp | Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
NZ599239A (en) * | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
AU2008268432B2 (en) * | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
NZ591955A (en) * | 2007-10-16 | 2011-10-28 | Repros Therapeutics Inc | Trans-clomiphene for diabetes mellitus type 2 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
JP2011500835A (ja) | 2007-10-25 | 2011-01-06 | エンドサイト,インコーポレイテッド | チューブリシン類および調製プロセス |
KR20180128078A (ko) | 2008-06-17 | 2018-11-30 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
KR20140069340A (ko) | 2008-08-04 | 2014-06-09 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
CN102369010A (zh) | 2009-04-06 | 2012-03-07 | 惠氏有限责任公司 | 用于乳腺癌的利用奈拉替尼的治疗方案 |
EP2580210B1 (en) | 2010-06-10 | 2017-03-01 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
JP2015535283A (ja) | 2012-11-02 | 2015-12-10 | レプロス セラピューティクス インコーポレイティド | 癌療法における使用のためのトランス−クロミフェン |
RU2560708C1 (ru) * | 2014-03-24 | 2015-08-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической и экспериментальной лимфологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКЭЛ" СО РАМН) | Способ воздействия на клетки гепатокарциномы в зависимости от стадии их дифференцировки нанопрепаратами лития |
AU2016331065B2 (en) | 2015-10-01 | 2021-04-29 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs |
EP3386968A4 (en) | 2015-12-09 | 2019-09-25 | The Board of Trustees of the University of Illinois | BENZOTHIOPHEN-BASED SELECTIVE ESTROGEN RECEPTOR-DOWN-REGULATING PREPARATIONS |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
SG11201903236SA (en) | 2016-10-11 | 2019-05-30 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME |
WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5023264A (en) | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5233036A (en) | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5411967A (en) | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5480989A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5262423A (en) | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
US5385910A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5389639A (en) | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5463048A (en) | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
US5491231A (en) | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
DE19624668A1 (de) * | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
-
2001
- 2001-08-06 AT AT01961914T patent/ATE278421T1/de not_active IP Right Cessation
- 2001-08-06 JP JP2002518948A patent/JP2004507465A/ja not_active Withdrawn
- 2001-08-06 US US09/923,217 patent/US6511986B2/en not_active Expired - Fee Related
- 2001-08-06 WO PCT/US2001/024615 patent/WO2002013802A2/en active IP Right Grant
- 2001-08-06 AU AU2001283139A patent/AU2001283139A1/en not_active Abandoned
- 2001-08-06 EP EP01961914A patent/EP1318837B1/en not_active Expired - Lifetime
- 2001-08-06 CN CNB018137539A patent/CN100448487C/zh not_active Expired - Fee Related
- 2001-08-06 PT PT01961914T patent/PT1318837E/pt unknown
- 2001-08-06 CA CA002416976A patent/CA2416976C/en not_active Expired - Fee Related
- 2001-08-06 ES ES01961914T patent/ES2228932T3/es not_active Expired - Lifetime
- 2001-08-06 DE DE60106281T patent/DE60106281T2/de not_active Expired - Fee Related
- 2001-08-06 MX MXPA03001245A patent/MXPA03001245A/es active IP Right Grant
- 2001-08-06 DK DK01961914T patent/DK1318837T3/da active
- 2001-08-10 AR ARP010103839A patent/AR033555A1/es unknown
-
2003
- 2003-12-12 HK HK03109077A patent/HK1056687A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20020045638A1 (en) | 2002-04-18 |
WO2002013802A3 (en) | 2003-03-27 |
WO2002013802A2 (en) | 2002-02-21 |
US6511986B2 (en) | 2003-01-28 |
ES2228932T3 (es) | 2005-04-16 |
AU2001283139A1 (en) | 2002-02-25 |
EP1318837B1 (en) | 2004-10-06 |
JP2004507465A (ja) | 2004-03-11 |
HK1056687A1 (en) | 2004-02-27 |
AR033555A1 (es) | 2003-12-26 |
DK1318837T3 (da) | 2005-01-10 |
DE60106281T2 (de) | 2005-02-24 |
CN1446106A (zh) | 2003-10-01 |
ATE278421T1 (de) | 2004-10-15 |
CN100448487C (zh) | 2009-01-07 |
MXPA03001245A (es) | 2003-05-27 |
EP1318837A2 (en) | 2003-06-18 |
CA2416976C (en) | 2008-05-20 |
CA2416976A1 (en) | 2002-02-21 |
DE60106281D1 (de) | 2004-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1318837E (pt) | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio | |
TR200102499T2 (tr) | Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi | |
PT1355889E (pt) | Derivados diamina triazole substituidos como inibidores de cinase | |
MY136097A (en) | Methods for treating osteoarthritis using an estrogen agonist/antagonist | |
DK1202724T3 (da) | Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer | |
TR200103756T2 (tr) | Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi. | |
DE60119028D1 (de) | Zugangspunkt und Authentifizierungsverfahren dafür | |
BR0311375A (pt) | Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero | |
ATE314371T1 (de) | Spiro-indole als y5-rezeptor antagonisten | |
DE69927354D1 (de) | Banknotenverarbeitungsvorrichtung | |
EP1427377A4 (en) | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISEASES USING BINDERS SPECIFIC TO THE PROSTATE-SPECIFIC MEMBRANEANT | |
NO20010539D0 (no) | Behandling av avhengighet og avhengighet-relatert oppförsel | |
DK1328269T4 (da) | Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme | |
BR0016681B1 (pt) | composição amaciante de tecidos, e, método de tratamento de tecido. | |
DE60132089D1 (de) | Vorrichtung zur behandlung von gasen miitels plasma | |
TW200628534A (en) | Retention and drainage aids | |
ZA200106160B (en) | Compositions and methods for treating cataracts. | |
BR0111601A (pt) | Método para o tratamento de doença cardiovascular | |
MA29394B1 (fr) | Anticorps | |
ATE406159T1 (de) | Behandlung von hyperlipidämie | |
BRPI0618198A2 (pt) | métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia | |
GB2425617B (en) | Device for preventing and treating myopia | |
EP1367026A4 (en) | METHOD, DEVICE AND TREATMENT TREATMENT SYSTEM | |
ATE288303T1 (de) | Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel | |
DK1441761T3 (da) | Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr |